Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEL-SCI Warning Letter Shows Pitfalls Of Website Presentations Of Investigational Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Website suggested that the unapproved cancer immunotherapy was safe and effective, FDA says.
Advertisement

Related Content

Describing An Investigational Drug On Your Website? Don’t Be Definitive About The Data, FDA Says
IND Promotion Quandary Again Trips Up Burzynski Research Institute
Equetro Web Pages Omit Risk Info, Make Unsupported Claims On Depression, FDA Says
FDA’s Rx Enforcement Letter Output Drops In 2011; OPDP Sees Improvement In Promotions
Cancer Drug Website Draws FDA's Ire For Promoting A Product In Clinical Trials
Internet-Focused Promotion, Warning Letters Both Up As FDA Guidance Nears
Internet-Focused Promotion, Warning Letters Both Up As FDA Guidance Nears

Topics

Advertisement
UsernamePublicRestriction

Register

PS072672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel